戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 eloid precursor cells transformed by the BCR/ABL oncogene.
2 of a primitive hematopoietic cell by the BCR/ABL oncogene.
3 hways, including those downstream of the bcr-abl oncogene.
4 ion, NK92 cells were transduced with the BCR/ABL oncogene.
5 ial for the transforming activity of the Bcr/Abl oncogene.
6 acute transforming retrovirus encoding the v-abl oncogene.
7 ith wild-type versus mutant forms of the Bcr/Abl oncogene.
8 insic oncogenic properties of the particular abl oncogene.
9  transformation of immature B cells by the v-abl oncogene.
10 eration, including transformation by the Bcr-Abl oncogene.
11 c leukemia (B-ALL) and is induced by the BCR-ABL oncogene.
12 protein that is a major substrate of the BCR/ABL oncogene.
13 mia (CML) that is driven by an inducible bcr-abl oncogene.
14 mechanisms in B-lineage cells transformed by ABL oncogenes.
15 I3K signaling in B-lineage transformation by ABL oncogenes.
16 ability of cells transformed by any of these ABL oncogenes.
17                                            C-abl oncogene 1, nonreceptor tyrosine kinase (ABL1) kinas
18 n of hematopoietic cells by the chimeric Bcr-Abl oncogene, a highly activated tyrosine kinase.
19                                        The v-Abl oncogene activates Jak-Stat signaling during transfo
20 dy the molecular mechanisms by which the bcr-abl oncogene acts in the disease progression of CML.
21 vo evidence for the proapoptotic function of Abl.Oncogene advance online publication, 18 December 200
22 dependent on continuous signaling of the BCR-ABL oncogene, also termed oncogene addiction, reprogramm
23 rate implicated in transformation by the bcr-abl oncogene and in signaling by cytokines.
24 IG) was developed as an inhibitor of the BCR-ABL oncogene and is among the most cardiotoxic of TKIs.
25  and pre-B cells are the target cells of the abl oncogene and numerous studies have suggested that St
26 the breakpoint cluster region (BCR)-abelson (ABL) oncogene and is effectively treated with tyrosine k
27 a-positive CML (Ph(+) CML) caused by the BCR-ABL oncogene, and in this condition, morgana underexpres
28 the Philadelphia (Ph) chromosome-encoded BCR-ABL oncogene, and these tend to have a poor prognosis.
29        Dami/HEL cells do not express the BCR/ABL oncogene, but increased constitutive phosphorylation
30  acutely transformed by the CML-specific BCR-ABL oncogene, but not by the serine kinase oncogene v-MO
31  lines K562 and BV173, which express the Bcr/Abl oncogene, but not in several Bcr/Abl-negative leukem
32 th a retrovirus vector carrying an activated ABL oncogene can be analysed.
33                                    Activated ABL oncogenes cause B-cell leukemias in mice and chronic
34                                      The BCR/ABL oncogene causes chronic myelogenous leukemia (CML),
35                                      The BCR/ABL oncogene causes chronic myelogenous leukemia, a myel
36                                      The BCR/ABL oncogene causes human chronic myelogenous leukemia (
37 oint cluster region-ABL tyrosine kinase (BCR-ABL) oncogene causes chronic myelogenous leukemia (CML).
38 e kinase inhibitors (TKIs) targeting the BCR-ABL oncogene constitutes an effective approach for the t
39           These results suggest that the BCR/ABL oncogene could alter the function of p130(CAS) in at
40           Cellular transformation by the BCR/ABL oncogene depends on the ABL-encoded tyrosine kinase
41 olytic human immune response against CML bcr-abl oncogene-derived peptides and provide a rationale fo
42  STAT5 might be one part of the mechanism of abl oncogene disease specificity.
43                                      The BCR/ABL oncogene encodes an activated tyrosine kinase that c
44                                      The BCR-ABL oncogene encodes an in-frame fusion protein containi
45  the chronic myeloid leukemia-associated BCR/ABL oncogene endows the adult hematopoietic stem cell wi
46 lphia chromosome (Ph) translocation, the BCR/ABL oncogene, exists in three principal forms (P190, P21
47          Here we demonstrate that in the Bcr-abl oncogene expressing human leukemia K562 cells, HDAC6
48 hether the apparent specificity of these two abl oncogenes for myeloid versus lymphoid neoplasms is d
49                                      The Bcr-Abl oncogene, found in Philadelphia chromosome-positive
50 ifferentiation and the expression of the BCR-ABL oncogene has direct relevance to CML biology as well
51 ransduction inhibitors - that target the bcr-abl oncogene have the potential to render such transplan
52 nd quantify known point mutations in the BCR-ABL oncogene in patients with chronic myelogenous leukem
53        Increased tyrosine kinase activity of abl oncogene in Philadelphia chromosome positive-leukemi
54 n lymphoblastic cells transformed by the BCR/ABL oncogene in response to BCR/ABL tyrosine kinase inhi
55    Expression of either the BCR-ABL or the v-abl oncogene in the factor-dependent murine myeloid cell
56 of the product of the Ph chromosome, the BCR/ABL oncogene, in mice by retroviral bone marrow transduc
57                                      The Bcr-abl oncogene induces hematopoietic cell transformation a
58 ative stress in cells transformed by the BCR-ABL oncogene is associated with increased DNA double-str
59 sformation of hematopoietic cells by the BCR/ABL oncogene is caused by perturbation of signal transdu
60 tic stem cell disorder in which an activated ABL oncogene is expressed and has been shown to play an
61 type of hematological neoplasm induced by an abl oncogene is influenced not only by what type of hema
62 emia and acute lymphocytic leukemia, the bcr-abl oncogene is involved in this process.
63      The tyrosine kinase activity of the Bcr/Abl oncogene is required for transformation of hematopoi
64                                      The BCR-ABL oncogene is responsible for most cases of chronic my
65               Our finding, that the P190 BCR/ABL oncogene is still capable of producing leukemia in t
66  various mouse models indicates that the BCR-ABL oncogene is the cause of chronic myeloid leukemia (C
67 otein kinase B (Akt) plays a pivotal role in Abl oncogene-mediated cell survival, we hypothesize that
68           The transforming activity of the v-Abl oncogene of Abelson murine leukemia virus (A-MuLV) i
69 onreceptor tyrosine kinase, encoded by the v-Abl oncogene of Abelson murine leukemia virus induces tr
70                           In addition, the v-abl oncogene of Abelson murine leukemia virus, whose pro
71                                        The v-abl oncogene of the Abelson murine leukemia virus (A-MuL
72 n the Src homology 2 (SH2) domain of the BCR/ABL oncogene on leukemogenesis was tested in a quantitat
73                                      The bcr-abl oncogene plays a critical role in causing chronic my
74                                      The bcr-abl oncogene plays a critical role in the pathogenesis o
75                                      The bcr-abl oncogene, present in 95% of patients with chronic my
76                                      The BCR/ABL oncogene product is one of the genes associated with
77         In hematopoietic cell lines, the BCR-ABL oncogene product, p210(BCR-ABL), interacts with a va
78                                        The v-Abl oncogene promotes cell cycle progression and inhibit
79             CML is associated with increased abl oncogene protein tyrosine kinase (PTK) activity.
80 the Abelson leukemia virus derived its Gag-v-Abl oncogene, recent results have linked ABL kinase acti
81  Transfection of each of the three activated ABL oncogenes resulted in rapid emergence of growth fact
82                                      The BCR/ABL oncogene results from a balanced translocation betwe
83 usly showed that mice expressing an Emicro-v-abl oncogene solely develop plasmacytomas.
84 pression in 32D cells transformed by the bcr-abl oncogene, suggesting that AATYK expression may be a
85 correlated with a specific region of the BCR-ABL oncogene, suggesting that activation (phosphorylatio
86 the appearance of point mutations in the BCR-ABL oncogene that confer resistance to this drug.
87 o/pre-B-cell transformation by v-Abl and BCR-ABL, oncogenes that cause leukemia in mice and humans.
88                   In cells harboring the bcr-abl oncogene, the activation (autophosphorylation) of Ca
89 In contrast, after transformation by the BCR/ABL oncogene, the chemotactic response to SDF-1alpha was
90 tion, Lnk deficiency cooperated with the BCR/ABL oncogene, the product of which does not directly int
91 n hematopoietic cells transformed by the BCR/ABL oncogene, this phosphatase complex was found to be c
92              The precise mechanisms by which Abl oncogenes transform hematopoietic cells are unknown.
93                                              ABL oncogenes trigger multiple signaling pathways whose
94 to compare the biological effects of various ABL oncogenes, we transformed two different factor-depen
95 id leukemia (CML) is the presence of the bcr-abl oncogene, which is associated with transforming abil
96 entified by its presence in the chimeric Bcr/Abl oncogene, which is causative for chronic myeloblasti
97      This drug specifically inhibits the BCR-ABL oncogene, which is required for progression.
98              Meg-01 cells express a p185 BCR/ABL oncogene, which may be responsible for the constitut